The Enabling Layer: Why Data, Platforms, and Governance Matter More Than Tools

Pharma R&D faces challenges not due to a lack of science, AI, or data, but because it lacks decision-grade systems. Despite significant investments in AI and multimodal platforms, high portfolio attrition persists because one of the bottleneck is the enabling layer. The structural architecture determining whether a scientific signal translates into successful capital allocation. When this layer is overlooked, AI redistributes uncertainty instead of reducing it, necessitating a focus on designing Evidence Continuity and Escalation Integrity to build truly decision-ready systems.